Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial

被引:29
|
作者
Juergens, Christine [1 ]
de Villiers, Pierre J. T. [2 ]
Moodley, Keymanthri [2 ]
Jayawardene, Deepthi [3 ]
Jansen, Kathrin U. [3 ]
Scott, Daniel A. [3 ]
Emini, Emilio A. [3 ]
Gruber, William C. [3 ]
Schmoele-Thoma, Beate [1 ]
机构
[1] Pfizer GmbH, Berlin, Germany
[2] Univ Stellenbosch, ZA-7505 Tygerberg, South Africa
[3] Pfizer Inc, Pearl River, NY USA
关键词
13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; adults; elderly; immunogenicity; PCV13; PPSV23; safety; OPSONOPHAGOCYTIC ASSAY; RESPONSES;
D O I
10.4161/hv.27998
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AlPO4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged >= 65 years (n = 105) not pre-vaccinated with PPSV23. Immune responses were measured by ELISA and opsonophagocytic activity assays 1 month postvaccination. Immunoglobulin G responses elicited by PCV13 with AlPO4 and PCV13 without AlPO4 were similar for the majority, and noninferior for all PCV13 serotypes. PCV13 with AlPO4 was generally more reactogenic, with reactions mainly mild or moderate. Thus, PCV13 with AlPO4 (hereafter PCV13) became the selected formulation. Immune responses to PCV13 were noninferior for all but one serotype and for most PCV13 serotypes superior to PPSV23. Vaccine sequence assessments showed that for PCV13/PPSV23, the initial PCV13 dose generally enhanced responses to a subsequent PPSV23 dose, compared with PPSV23 alone. For PCV13/PCV13, a second dose did not enhance the first dose response when given after 1 year. For PCV13/PPSV23/PCV13, priming with PCV13 (vaccination 1) did not protect against lower responses induced by PPSV23 to subsequent PCV13 (vaccination 3). In conclusion, the pediatric PCV13 formulation with AlPO4 is well tolerated and immunogenic in adults, is generally more immunogenic than PPSV23, and subsequent vaccination with PPSV23 is possible if required.
引用
收藏
页码:1343 / 1353
页数:11
相关论文
共 50 条
  • [21] Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico
    Gutierrez Brito, Maricruz
    Thompson, Allison
    Girgenti, Douglas
    Giardina, Peter C.
    Sarkozy, Denise A.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2013, 33 (06): : 414 - 421
  • [22] Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers
    Yeh, Sylvia H.
    Gurtman, Alejandra
    Hurley, David C.
    Block, Stan L.
    Schwartz, Richard H.
    Patterson, Scott
    Jansen, Kathrin U.
    Love, Jack
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    PEDIATRICS, 2010, 126 (03) : E493 - E505
  • [23] Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
    Simon, Michael W.
    Bataille, Regine
    Caldwell, Nicole S.
    Gessner, Bradford D.
    Jodar, Luis
    Lamberth, Erik
    Peng, Yahong
    Scott, Daniel A.
    Lei, Lanyu
    Giardina, Peter C.
    Gruber, William C.
    Jansen, Kathrin U.
    Thompson, Allison
    Watson, Wendy
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [24] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine
    Frenck, Robert, Jr.
    Thompson, Allison
    Yeh, Sylvia H.
    London, Arnold
    Sidhu, Mohinder S.
    Patterson, Scott
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (12) : 1086 - 1091
  • [25] Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial
    Okinaka, Keiji
    Akeda, Yukihiro
    Inamoto, Yoshihiro
    Fuji, Shigeo
    Ito, Ayumu
    Tanaka, Takashi
    Kurosawa, Saiko
    Kim, Sung-Won
    Tanosaki, Ryuji
    Yamashita, Takuya
    Ohwada, Chikako
    Kurata, Keiji
    Mori, Takeshi
    Onozawa, Masahiro
    Takano, Kuniko
    Yokoyama, Hiroki
    Koh, Katsuyoshi
    Nagafuji, Koji
    Nakayama, Kazutaka
    Sakura, Toru
    Takahashi, Tsutomu
    Oishi, Kazunori
    Fukuda, Takahiro
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (04) : 482 - 489
  • [26] Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
    Belmonti, Simone
    Rossetti, Barbara
    Modica, Sara
    Paglicci, Lorenzo
    Borghetti, Alberto
    Ciccullo, Arturo
    Picarelli, Chiara
    Cauda, Roberto
    De Luca, Andrea
    Montagnani, Francesca
    Lombardi, Francesca
    INFECTIOUS DISEASES AND THERAPY, 2019, 8 (03) : 453 - 462
  • [27] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Tomczyk, Sara
    Bennett, Nancy M.
    Stoecker, Charles
    Gierke, Ryan
    Moore, Matthew R.
    Whitney, Cynthia G.
    Hadler, Stephen
    Pilishvili, Tamara
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (37): : 822 - 825
  • [28] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
    Matanock, Almea
    Lee, Grace
    Gierke, Ryan
    Kobayashi, Miwako
    Leidner, Andrew
    Pilishvili, Tamara
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (46): : 1069 - 1075
  • [29] Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine
    Quinet, Beatrice
    Laudat, France
    Gurtman, Alejandra
    Patterson, Scott
    Sidhu, Mohinder
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (10) : 1065 - 1076
  • [30] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Remschmidt, Cornelius
    Harder, Thomas
    Wichmann, Ole
    Bogdan, Christian
    Falkenhorst, Gerhard
    BMC INFECTIOUS DISEASES, 2016, 16